ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Anti-TNF Drugs"

  • Abstract Number: 0291 • ACR Convergence 2024

    Safety of Biologic Therapy in Kidney Transplant Recipients with Inflammatory Diseases: Real-world Experience from a Tertiary Medical Center

    Victoria Furer1, Omer Kersh2, Mark Berman3, Ayelet Grupper2 and Ori Elkayam4, 1Tel Aviv Medical Center, Tel Aviv, Israel, 2Tel Aviv Sourasky Medical Center, Tel Aviv, Tel Aviv, Israel, 3Tel Aviv Sourasky Medical Center, Kefar sava, Israel, 4Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

    Background/Purpose: Management of solid-organ transplant (SOT) recipients with systemic inflammatory diseases represents a clinical challenge in the paucity of data related to the safety of…
  • Abstract Number: 1401 • ACR Convergence 2024

    Risk of Malignancy with TNF-α Inhibitors in Patients with Rheumatoid Arthritis

    Omair Khan1, Syed Mujtaba Baqir2, Azka Naeem2, Muhammad Hashim khan2, Tharun Shyam2, Kseniya Slobodyanyuk3 and Anastasia Slobodnick4, 1Maimonides Medical Center, Council Bluffs, IA, 2Maimonides Medical Center, Brooklyn, NY, 3Maimonides Medical Center, Manhattan, NY, 4Northwell, Staten Island, NY

    Background/Purpose: Rheumatoid arthritis (RA) is associated with various comorbidities and complications among which cancer has been highlighted in literature. This cancer risk has been attributed…
  • Abstract Number: 2598 • ACR Convergence 2024

    p300 KAT Inhibition Selectively Targets Multiple Cell Types Involved in Chronic Inflammation and Downregulates Key Inflammatory Cytokines

    Zhihua Ma, Luis Carvajal, Andrew Chen, Rosa Villagomez, Yare calderon, Tamara Hopkins, Hua Gao, Benjamin Trotter, Charles Lin and Peter Rahl, Kronos Bio, Cambridge, MA

    Background/Purpose: Across inflammatory and autoimmune diseases, pathologic signaling converges in the nucleus to elevate transcription of numerous inflammatory effectors such as cytokines, chemokines and antibodies.…
  • Abstract Number: 0356 • ACR Convergence 2024

    Patient Satisfaction and Experience After a Switch to a Citrate-free High-concentration Adalimumab Biosimilar. Results from a Prospective Multicentric Real-world Study

    Hubert Marotte1, Laure Gossec2, Vered ABITBOL3, Eric SENBEL4, Guillaume BONNAUD5, Xavier ROBLIN6, Yoram BOUHNIK7, Stéphane NANCEY8, Nicolas MATHIEU9, jérôme FILIPPI10, Lucine VUITTON11, Stéphane NAHON12, Azeddine Dellal12, Alice DENIS13, Caroline HABAUZIT13, Salim BENKHALIFA13 and Guillaume BOUGUEN14, 1Université Jean Monnet, CHU Saint-Etienne, Mines Saint-Etienne, INSERM SAINBIOSE 1059, Saint-Etienne, France, 2Sorbonne Université, Paris, France, 3Cochin University Hospital, Paris, France, 4Medical practice, Marseille, Marseille, France, 5Ambroise Paré Clinic, Toulouse, France, 6Saint-Etienne University Hospital, Saint-Etienne, France, 7Institut des MICI, Paris IBD Center, Neuilly-Sur-Seine, France, 8Hospices Civils de Lyon, Lyon, France, 9Clinic of Cèdres, Echirolles, France, 10Saint-Jean Clinic, Cagnes sur Mer, France, 11Besançon university hospital, Besançon, France, 12Groupe Hospitalier Intercommunal Le Raincy-Montfermeil, Montfermeil, France, 13Celltrion Healthcare France, Issy Les Moulineaux, France, 14Rennes University Hospital, Rennes, France

    Background/Purpose: Biosimilars (BioS) are cost-effective alternatives to reference products for patients with chronic inflammatory rheumatic diseases (CIRD) and inflammatory bowel diseases (IBD), but treatment adherence…
  • Abstract Number: 1452 • ACR Convergence 2024

    Assessing Responsiveness of Outcome Measures for Children with Axial Juvenile Spondyloarthritis (JSpA)

    Timothy Brandon1, Rui Xiao2, Cassandra Muir1, Matthew Stoll3, Daniel Lovell4, Edward Oberle5, Nancy Chauvin6, Michael Francavilla7, Walter Maksymowych8 and Pamela Weiss9, 1Children's Hospital of Philadelphia, Philadelphia, PA, 2University of Pennsylvania, Philadelphia, PA, 3University of Alabama at Birmingham, Birmingham, AL, 4Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 5Nationwide Children's Hospital, Columbus, OH, 6The Imaging Institute @ The Cleveland Clinic, Cleveland, OH, 7Department of Radiology, Whiddon College of Medicine, University of South Alabama, Mobile, AL, 8University of Alberta, Edmonton, AB, Canada, 9Children's Hospital of Philadelphia, Philadelphia, PA

    Background/Purpose: Trials for patients with juvenile spondyloarthritis (JSpA) and axial disease are scarce. We assessed the responsiveness of measures for use in trials of patients…
  • Abstract Number: 2619 • ACR Convergence 2024

    Safety Outcomes of Routine Blood Tests for Monitoring of Biologic and Targeted Synthetic Therapies in Inflammatory Arthritis Patients

    Tali Eviatar1, Iftach Sagy2, Elad Brav2, Amir Bieber3, Victoria Furer4 and Ori Elkayam5, 1Tel Aviv Medical Center, Ramat Gan, HaMerkaz, Israel, 2Soroka Medical Cenrter, beer sheva, Israel, 3Emek Medical Center, Clalit Health Services, Raanana, Israel, 4Tel Aviv Medical Center, Tel Aviv, Israel, 5Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

    Background/Purpose: Patients treated with biologic or targeted synthetic (b/ts) DMARDs are recommended to perform safety blood monitoring every 3 months in the absence of strong…
  • Abstract Number: 0363 • ACR Convergence 2024

    Comparative Risk of Demyelinating Diseases Among Patients on TNF-Alpha Inhibitors: A Cohort Study Using the TriNetX Database

    Rafal Ali1, Yurilu Gonzalez Moret2, Roua Hussein3 and Fabian Rodriguez4, 1Jefferson Einstein Philadelphia, Lansdale, PA, 2Jefferson Einstein Philadelphia, Philadelphia, PA, 3Al-Mustansiriyah University/ college of medicine, New York, NY, 4Jefferson Einstein Hospital, Philadelphia, PA

    Background/Purpose: TNF-alpha inhibitors are widely used in the field of rheumatology and have been linked to various possible adverse events, including demyelinating diseases. This association…
  • Abstract Number: 1679 • ACR Convergence 2024

    Differential Pharmacodynamic Changes of Circulated Immune Subsets After Treatment with Abatacept or Adalimumab in Patients with ACPA+ Early RA in the AMPLIFIED Study

    Nathanial Eddy1, Jane Buckner2, Paul Emery3, Michael Weinblatt4, Vivian Bykerk5, Andrew Cope6, Gerd Burmester7, Yoshiya Tanaka8, Gustavo Citera9, Peter Nash10, Quentin Dornic11, Peter Schafer12, Sheila Kelly13, Michael Maldonado11 and Jinqi Liu11, 1Bristol Myers Squibb, Princeton, 2Benaroya Research Institute, Seattle, WA, 3University of Leeds, Leeds, United Kingdom, 4Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, 5Hospital For Special Surgery, New York, NY, 6King's College London, London, United Kingdom, 7Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, 8Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, 9Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, 10Griffith University, Brisbane, Australia, 11Bristol Myers Squibb, Princeton, NJ, 12Bristol Myers Squibb, BELLE MEAD, NJ, 13Bristol Myers Squibb, Doylestown, PA

    Background/Purpose: Despite considerable advances in pharmacologic approaches to RA management, a better understanding of the underlying immunopathology is still needed.1,2 A dysregulated immune system is…
  • Abstract Number: 0465 • ACR Convergence 2024

    Therapeutic Drug Monitoring of the Adalimumab Biosimilar (AMJEVITA™, Adalimumab-atto) Using Originator Adalimumab and Anti-Adalimumab Antibody Assays

    Monique Bastidas1, Lythou Yeo1, Susie Magpantay1, Judah Scott1, Mike Zikry1, Wayne Galdamez1, Jane Yang2 and Kelly Chun1, 1Labcorp, Calabasas, CA, 2LabCorp, Weston, MA

    Background/Purpose: Treatment of RA with biologic TNF inhibitors is effective in reducing disease activity and improving radiographic progression outcomes. Therapeutic drug monitoring (TDM) of adalimumab…
  • Abstract Number: 1850 • ACR Convergence 2024

    Exhausted T-cells Are Increased in Autoimmune Diseases and Predict Response to Anti-TNF in RA and SPA Patients

    Samuel Bitoun1, Marie Naigeon2, Matthieu Roulleaux- Dugage2, Caroline De Oliveira2, Caroline Berthot2, Xavier Mariette3, Gaetane Nocturne3 and Nathalie Chaput-Gras2, 1Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin-Bicetre, France, 2Laboratoire d'immunomonitoring en Oncologie, INSERM US23, CNRS UMS 3655, Gustave Roussy,, Villejuif, France, 3Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France

    Background/Purpose: Exhaustion can occur after prolonged activation of T cells limiting their immunosurveillance function leading to cancer emergence. Among the exhaustion markers expressed on T…
  • Abstract Number: 0519 • ACR Convergence 2024

    Comparable Malignancy Risk of Janus Kinase Inhibitors with Conventional Synthetic and Biologic DMARDs in Asian Patients with Rheumatoid Arthritis: A Comprehensive Analysis from Two Medical Centers

    Ming‑Han Chen1, Mao-Yuan Chen2, Shih-Hsin Chang3 and DER-YUAN CHEN4, 1Division of Allergy, Immunology & Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, Taipei, Taiwan, 2Division of Allergy, Immunology & Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan (Republic of China), 3Rheumatology and Immunology Center, China Medical University Hospital, Taichung, Taiwan (Republic of China), 4heumatology and Immunology Center, China Medical University Hospital, Taichung, Taiwan (Republic of China)

    Background/Purpose: JAK inhibitors (JAKi) and biologic disease-modifying antirheumatic drugs (bDMARDs) have proven efficacy in the treatment of rheumatoid arthritis (RA). However, their potential for increasing…
  • Abstract Number: 1892 • ACR Convergence 2024

    Early Tumor Necrosis Factor Inhibitor Initiation and Chronic Opioid Use in Individuals with Axial Spondyloarthritis

    Eva Petrow1, Jose Meade Aguilar2, Christine Peloquin3, S. Reza Jafarzadeh3, Tuhina Neogi3, Maureen Dubreuil4 and Jean Liew3, 1Boston University/Boston Medical Center, Boston, MA, 2Boston Medical Center, Boston, MA, 3Boston University Chobanian & Avedisian School of Medicine, Boston, MA, 4Section of Rheumatology, Boston University School of Medicine, Boston, MA

    Background/Purpose: Patients with axial spondyloarthritis (axSpA) bear a substantial burden of chronic opioid use despite the availability of effective treatments like tumor necrosis factor inhibitors…
  • Abstract Number: 0264 • ACR Convergence 2023

    A Novel Role for Rheumatologists: Managing Idiopathic Granulomatous Mastitis

    Marcia Genta1 and Allison DiPasquale2, 1Dallas Arthritis Center, Dallas, TX, 2Texas Oncology - Medical City Dallas, Dallas, TX

    Background/Purpose: Idiopathic Granulomatous Mastitis (IGM) is a rare often self-limited chronic inflammatory breast disease of unknown etiology characterized by non-caseating granulomas in breast tissue, affecting…
  • Abstract Number: 0779 • ACR Convergence 2023

    Influence of Sex on the Persistence of Different Classes of Targeted Therapies for Psoriatic Arthritis: A Cohort Study of 14,778 Patients from the French Health Insurance Database (SNDS)

    Laura PINA VEGAS1, Laetitia Penso2, Emilie Sbidian3 and pascal claudepierre4, 1Henri Mondor University Hospital (APHP), Rheumatology Department, Créteil, France, 2Université Paris Est Créteil, Créteil, France, 3Hôpital Henri Mondor, Université Paris Est Créteil, Créteil, France, 4Universitary Henri Mondor Hospital, Creteil, France

    Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous condition and sex differences in phenotypic presentation, disease trajectory, and treatment response have been reported. Nevertheless, it remains…
  • Abstract Number: 1559 • ACR Convergence 2023

    Comparison of Treatment with Adalimumab, Infliximab and Certolizumab in Refractory Cystoid Macular Edema Due to Behçet Disease

    Nuria Barroso-Garcia1, Jose Luis Martin-Varillas2, Lara Sanchez-Bilbao3, Ivan Ferraz Amaro4, Vanesa Calvo Río5, Alfredo Adán6, Inés Hernanz-Rodriguez7, Emma Beltran-Catalan8, David Diaz-Valle9, Marisa Hernandez-Garfella10, Lucia Martinez-Costa11, Manuel Diaz-Llopis12, Jose M Herreras13, Olga Maiz-Alonso14, Ignacio Torre-Salaberri15, Antonio Atanes Sandoval16, Santos Insua-Vilariño17, Raquel Almodovar18, Patricia Fanlo-Mateo19, Juan Ramon De Dios20, Angel Garcia-Aparicio21, Sergio rodriguez-Montero22, Vega Jovani23, Patricia Moya24, Eva Peña Sainz-Pardo25, Jose Luis Hernandez26 and Ricardo Blanco27, 1Hospital Universitario Puerta del Mar, Cadiz, Spain, 2Hospital de Laredo, Laredo, Spain, 3Hospital Universitario Marques de Valdecilla, Santander, Spain, 4Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, 5Valdecilla Hospital, Santander, Spain, 6Oftalmology, Hospital Clinic de Barcelona, Barcelona, Spain, 7Ophthalmology, Hospital Clinic de Barcelona, Barcelona, Spain, 8HOSPITAL DEL MAR, Barcelona, Spain, 9Hospital Clinico San Carlos, Madrid, Spain, 10Ophthalmology, Hospital Universitario General Valencia, Valencia, Spain, 11Ophthalmology, Hospital Universitario Doctor Peset, Valencia, Spain, 12Ophthalmology, Hospital Universitario La Fe, Valencia, Spain, 13Ophthalmology, Hospital Clínico Universitario de Valladolid, Valladolid, Spain, 14University Hospital Donostia, San Sebastian, Spain, 15Hospital Universitario de Basurto, Bilbao, Spain, 16Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC)., A Coruña, Spain, 17Rheumatology, Hospital Universitario de Santiago de Compostela, Santiago Compostela, Spain, 18Alcorcón Foundation University Hospital, Madrid, Spain, 19Internal Medicine, Complejo Hospitalario Universitario de Navarra, Pamplona, Spain, 20Osakidetza, Vitoria, Spain, 21Hospital Universitario de Toledo, Toledo, Spain, 22Rheumatology, Hospital Universitario Virgen de Valme, Sevilla, Spain, 23Department of Rheumatology, Hospital General Universitario Dr. Balmis, Alicante, Spain, 24Hospital de Santa Creu i Sant Pau, Barcelona, Spain, 25Pediatric, Hospital 12 de Octubre, Madrid, Spain, 26Rheumatology, Ophthalmology and Internal Medicine, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 27Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

    Background/Purpose: Cystoid macular edema (CME) is the leading cause of blindness in non-infectious uveitis. One of the most frequently associated conditions is Behçet's disease (BD)…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 18
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology